KeyBanc initiated coverage of AptarGroup (ATR) with an Overweight rating and $220 price target The firm believes the company’s position as a leader in inhalable drug delivery systems and its growing position in advanced delivery technologies are not reflected in the share price. AptarGroup has been transitioning from a diversified packaging company to a more concentrated healthcare business, the analyst tells investors in a research note. KeyBanc believes the company’s revenue growth will accelerate and margins expand as it continues the transition.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATR:
- AptarGroup: Strong Performance and Growth Potential Amid Temporary Challenges
- AptarGroup price target lowered to $172 from $182 at Raymond James
- AptarGroup price target lowered to $153 from $173 at Wells Fargo
- AptarGroup Reports Strong Q2 2025 Results
- AptarGroup Earnings Call: Pharma and Closures Shine